Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis

Brief description of study

This study is being done to answer the following questions: Does starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, result in a significant improvement in overall survival (OS) (time being alive) for patients with your type of cancer? Does additional treatment with chemotherapy following immunotherapy alone also improve overall survival? We are doing this study because we want to find out whether either of these two usual approaches to treating your type of cancer is better or worse than the other. The usual approach is defined as care most people get for PD-L1 positive non-squamous non-small cell lung cancer.


Clinical Study Identifier: s19-00312
ClinicalTrials.gov Identifier: NCT03793179
Principal Investigator: Vamsidhar Velcheti
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.